Overview

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-650032 in subjects with chronic hepatitis C infection
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir